摘要
吉非替尼(gefitinib)是第一代表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosinekinase inhibitors,EGFR-TKIs)类靶向药物,目前主要用于非小细胞肺癌,特别是EGFR突变型晚期肺腺癌的一二线治疗中。然而,对于靶向药物的治疗模式并无明显定论,存在一定的争议。随着患者生存期延长,不断地出现耐药及并发症。目前普遍认同吉非替尼的出现使肺腺癌患者生存期延长,但是治疗模式的选择不管是一线使用吉非替尼、化疗后维持使用吉非替尼或交替使用化疗及吉非替尼,并未明显延长生存期,而是决定了患者的客观缓解率及生活质量,本文对目前关于吉非替尼治疗模式研究进展作一综述。
Gefitinib is the first targeted drugs representative of epidermal growth factor receptor tyrosine kinase inhibitor,mainly for nonsmall cell lung cancer and particular in second- line treatment of advanced EGFR mutant lung adenocarcinoma.However,there is a certain controversy for targeted drug treatment modal and have no obvious conclusion.With the prolonged survival of patients,the emergence of drug complications continue to occur. It is generally recognized that gefitinib has prolonged survival of patients with lung cancer, but the choice of whether it is the first-line treatment modal or combining gefitinib with chemotherapy to maintain the use of gefitinib or alternative use of chemotherapy and gefitinib, did not significantly prolong survival, but decided the objective response rate and quality of life of patients.therefore, this paper will present research progress on gefitinib treatment modal for Nepalese reviewed.
出处
《武警后勤学院学报（医学版）》
CAS
2015年第11期923-926,930,共5页
Journal of Logistics University of PAP（Medical Sciences）
关键词
非小细胞肺癌
耐药性
吉非替尼
Non-small cell lung cancer
Drug resistance
Gefitinib
